Bank of America Corp
Change company Symbol lookup
Select an option...
BAC Bank of America Corp
SU Suncor Energy Inc
USOI Credit Suisse X-Links Crude Oil Shares Covered Call ETNs
GE General Electric Co
HLNE Hamilton Lane Inc
HLI Houlihan Lokey Inc
HIG Hartford Financial Services Group Inc
HIBB Hibbett Sports Inc
HHC Howard Hughes Corp
VPRB VPR Brands LP
Go

Financials : Banks | Large Cap Value
Company profile

Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers and others with a range of banking, investing, asset management and other financial and risk management products and services. The Company, through its banking and various non-bank subsidiaries, throughout the United States and in international markets, provides a range of banking and non-bank financial services and products through four business segments: Consumer Banking, which comprises Deposits and Consumer Lending; Global Wealth & Investment Management, which consists of two primary businesses: Merrill Lynch Global Wealth Management and U.S. Trust, Bank of America Private Wealth Management; Global Banking, which provides a range of lending-related products and services; Global Markets, which offers sales and trading services, and All Other, which consists of equity investments, residual expense allocations and other.

Closing Price
$26.11
Day's Change
0.64 (2.51%)
Bid
--
Ask
--
B/A Size
--
Day's High
26.19
Day's Low
25.26
Volume
(Above Average)
Volume:
63,354,498

10-day average volume:
56,075,071
63,354,498

BioNTech's stock halted, Pfizer shares jump on promising COVID-19 vaccine data

9:36 am ET July 1, 2020 (MarketWatch)
Print

BioNTech's (BNTX) stock was halted and shares of Pfizer Inc. (PFE) gained 4.7% in trading on Wednesday morning after the companies said that all 24 participants in the Phase 1/2 clinical trial who received one of two lower doses of a COVID-19 vaccine candidate developed neutralizing antibodies. This data was shared by the companies and was also published in a preprint study (https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1.full.pdf), which means it has not been peer-reviewed. The study has 45 participants between the ages of 18 and 55 years old who were randomized and vaccinated; 24 of which received two rounds of two lower doses of the vaccine candidate. (Twelve participants received one high dose, and nine received two doses of the placebo.) The antibody findings are important because they indicate that the experimental vaccine can generate antibodies at the same level or higher than those seen in convalescent sera, which is collected from people who have recovered from COVID-19. There were no serious adverse events reported in the trial, although some reported pain in the area of the body where the investigational vaccine was administered. Pfizer said in a news release that additional data from this trial will inform the selection of the candidate - the companies are evaluating four COVID-19 vaccine candidates - and dosing level for the Phase 2b/3 study, which could begin this month, with up to 30,000 participants. Since the start of the year, BioNTech's stock is up 97.0%, shares of Pfizer are down 16.5%, and the S&P 500 is down 4.0%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 01, 2020 09:36 ET (13:36 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.